Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy

Rheumatology (United Kingdom)

Volumn 54, Issue 9, 2015, Pages 1699-1708

  Cornec, Divi ^a,b   Devauchelle Pensec, Valérie ^a,b   Mariette, Xavier ^c   Jousse Joulin, Sandrine ^a,b   Berthelot, Jean Marie ^d   Perdriger, Aleth ^e   Puéchal, Xavier ^f,g   Le Guern, Véronique ^g   Sibilia, Jean ^h   Gottenberg, Jacques Eric ^h   Chiche, Laurent ^i,j   Hachulla, Eric ^k   Hatron, Pierre Yves ^k   Goeb, Vincent ^l   Hayem, Gilles ^m   Morel, Jacques ⁿ   Zarnitsky, Charles ^o   Dubost, Jean Jacques ^p   Seror, Raphaèle ^c   Pers, Jacques Olivier ^b,q   Meiners, Petra M ^r   Vissink, Arjan ^r   Bootsma, Hendrika ^r   Nowak, Emmanuel ^s   Saraux, Alain ^a,b   more..

^a SERVICE DE RHUMATOLOGIE   (France)

^b Universite de Brest   (France)

^c BICÊTRE HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e SERVICE DE RHUMATOLOGIE   (France)

^f Service de Rhumatologie   (France)

^g Hopital Cochin ^*  (France)

^h UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁱ HÔPITAL DE LA CONCEPTION   (France)

^j Department of Digestive Surgery   (France)

^k UNIV LILLE   (France)

^l Dept de Médecine Interne Ctr Hosp Univ Rouen Boisguillaume   (France)

^m BICHAT HOSPITAL   (France)

ⁿ LAPEYRONIE HOSPITAL   (France)

^o Service de Rhumatologie   (France)

^p SERVICE DE RHUMATOLOGIE   (France)

^q CHU MORVAN   (France)

^r UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^s BREST UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Efficacy; Outcome measures; Primary Sj gren's syndrome; Rituximab

Indexed keywords

INFLIXIMAB; PLACEBO; RITUXIMAB;

ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERANCE; DRY EYE; FATIGUE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SJOEGREN SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 84983201185     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev114     Document Type: Article

References (30)

1. Cornec D, Chiche L. Is primary Sjögren's syndrome an orphan disease? A critical appraisal of prevalence studies in Europe. Ann Rheum Dis 2015;74:e25.
2. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010;304:452-60.
3. Cornec D, Devauchelle-Pensec V, Tobón GJ et al. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment. J Autoimmun 2012;39:161-7.
4. Cornec D, Saraux A, Devauchelle-Pensec V, Clodic C, Pers J-O. The future of B cell-targeted therapies in Sjögren's syndrome. Immunotherapy 2013;5:639-46.
5. Pijpe J, van Imhoff GW, Spijkervet FKL et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.
6. Devauchelle-Pensec V, Pennec Y, Morvan J et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Care Res 2007;57:310-7.
7. Carubbi F, Cipriani P, Marrelli A et al. Efficacy and safety of rituximab treatment in early primary Sjogren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013;15:R172.
8. Dass S, Bowman SJ, Vital EM et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4.
9. Meijer JM, Meiners PM, Vissink A et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
10. Brown S, Coy NN, Pitzalis C et al. The TRACTISS protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjogren's Syndrome. BMC Musculoskelet Disord 2014;15:21.
11. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014;160:233-42.
12. Seror R, Theander E, Bootsma H et al. Outcome measures for primary Sjögren's syndrome: a comprehensive review. J Autoimmun 2014;51:51-6. http://www.sciencedirect.com/science/article/pii/S0896841113001571 (11 February 2014, date last accessed).
13. Seror R, Ravaud P, Bowman SJ et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9.
14. Seror R, Ravaud P, Mariette X et al. EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann Rheum Dis 2011;70:968-72.
15. Seror R, Theander E, Brun JG et al. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859-66.
16. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
17. Mariette X, Ravaud P, Steinfeld S et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled trial of remicade in primary Sjögren's syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6.
18. Tugwell P, Bombardier C. A methodologic framework for developing and selecting endpoints in clinical trials. J Rheumatol 1982;9:758-62.
19. Hernández-Molina G, Sánchez-Hernández T. Clinimetric methods in Sjögren's syndrome. Semin Arthritis Rheum 2013;42:627-39.
20. Jorkjend L, Johansson A, Johansson A-K, Bergenholtz A. Resting and stimulated whole salivary flow rates in Sjögren's syndrome patients over time: a diagnostic aid for subsidized dental care? Acta Odontol Scand 2004;62:264-8
21. Pijpe J, Kalk WWI, Bootsma H et al. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. Ann Rheum Dis 2007;66:107-12.
22. Jousse-Joulin S, Devauchelle-Pensec V, Morvan J et al. Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: quantitative and Doppler waveform analysis. Biol Targets Ther 2007;1:311-9.
23. Bendaoud B, Pennec YL, Lelong A et al. IgA-containing immune complexes in the circulation of patients with primary Sjögren's syndrome. J Autoimmun 1991;4:177-84.
24. Witte T, Hartung K, Sachse C et al. Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group. Rheumatol Int 2000;19:107-11.
25. Sankar V, Brennan MT, Kok MR et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, doubleblind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5.
26. Ramos-Casals M, Brito-Zerón P, Solans R et al. Systemic involvement in primary Sjögren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 2014;53:321-31.
27. Baldini C, Pepe P, Quartuccio L et al. Primary Sjögren's syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatology 2013;53:839-44.
28. Moerman RV, Arends S, Meiners PM et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73:472-4.
29. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
30. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.